Clinical Trial Update: GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This clinical trial update indicates that GR1803 is being evaluated in a Phase 2 study for relapsed/refractory multiple myeloma, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GR1803

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING